Gene Editing Can Now Cure Rare Disease. Here Is How Families Can Actually Access These Treatments Today

On April 9, 2026, The New York Times published an opinion piece making a case that has become impossible to ignore: we now have the scientific tools to edit genes and cure disease, and the bottleneck is no longer the science. It is everything that happens between the science and the child.

If you read that piece as a parent of a child with a rare genetic disease, you probably had two reactions at once. Hope, because it is true. And frustration, because the article raises the question every family in our community asks in the middle of the night: if this works, why can't my child get it?

This article is the practical companion to the NYT piece. We will explain what is actually possible for rare disease families in 2026, which treatment pathways exist right now, what they cost, how to enter them, and where the real operational gap is. If your child has a genetic diagnosis and you want to move from reading about gene editing to actually pursuing it, start here.

What the NYT Piece Got Right

The scientific case the NYT makes is correct and worth restating clearly for any family new to this space.

Gene editing works in humans. In May 2025, a baby known as KJ Muldoon became the first patient in history to receive a custom CRISPR base-editing therapy designed for his specific mutation. He had CPS1 deficiency, a metabolic disorder that kills roughly half of affected infants. The therapy was designed, manufactured, and delivered to his liver in about six months. He was discharged from Children's Hospital of Philadelphia in June 2025 and is growing normally.

Such speed to producing a clinic-grade CRISPR for a genetic disease has no precedent in our field. Not even close.

Dr. Fyodor Urnov, Innovative Genomics Institute, May 2025

Sickle cell disease can now be cured with gene editing. In April 2026, the Cleveland Clinic and partners published RUBY trial results in NEJM: 27 out of 28 patients treated with a gene-edited cell therapy were free of painful sickle cell crises after treatment. This is a functional cure for one of the most common severe genetic diseases in the world.

More than 30 patients have received personalized ASO therapies through n-Lorem, a nonprofit that develops custom antisense oligonucleotides for nano-rare diseases (patients with mutations found in 1 to 30 people worldwide). Nearly all have shown clinical benefit. n-Lorem provides these treatments for free, for life.

The FDA has published a framework that supports individualized therapies. On February 23, 2026, the FDA published a "plausible mechanism" framework that formalizes regulatory pathways for therapies developed for single patients or very small cohorts. This was not a minor update. It is the most significant regulatory shift for individualized medicine in decades.

So the NYT is right. The science works. The technology exists. Patients have been cured. This is not theoretical.

The Two Gaps the NYT Piece Points To

The harder question, and the one families actually need answered, is why these successes have not scaled. If Baby KJ proved that a custom CRISPR therapy can be built in six months, why can't the next hundred babies get one? If n-Lorem has treated 30 nano-rare patients, why not 3,000?

There are two distinct gaps, and they require different solutions.

Gap 1: The Access Gap

The access gap is about eligibility and visibility. Most families with a rare genetic diagnosis never learn that a personalized therapy might be possible for their child. They are told "there is nothing we can do" and sent home. Of the families who do find their way to a program, most are turned away because their disease does not match the narrow eligibility criteria of the few organizations offering custom therapies today.

n-Lorem is remarkable, but it focuses on ASO-addressable mutations in the liver, kidney, eye, and central nervous system. If your child's disease affects muscle, bone, heart, or lung, n-Lorem cannot help. Academic centers like CHOP run bespoke programs, but only for patients who happen to match an active project. There is no "front door" for the millions of families whose disease falls outside the current patchwork of programs.

The access gap is solved by giving every family with a genetic diagnosis a real evaluation of what is possible for their specific mutation, regardless of which tissue is affected or which modality is needed.

Gap 2: The Logistics and Operations Gap

Even when a family is told "yes, a personalized therapy is possible for your child," what happens next is the problem no one talks about. Building a custom therapy requires coordinating 20 or more specialized vendors, each with their own timelines, contracts, quality standards, and technical requirements. Patient cells have to be established at one lab. The variant has to be analyzed by a bioinformatics team. The therapy has to be designed by a chemistry group. Preclinical testing happens at a different CRO. GMP manufacturing happens at another. Regulatory filing is yet another specialty. Coordinating all of this takes 6 to 12 months of full-time project management from someone who understands both the science and the operations.

Most families cannot do this alone. Most academic labs cannot either, which is why bespoke programs at hospitals take years to deliver even when the science is ready on day one. Baby KJ's treatment happened in six months because an elite team at CHOP, Penn, and IGI threw everything they had at a single case. That is not a scalable model. The next 100 families cannot each get a dedicated team of Nobel-adjacent scientists working around the clock.

The logistics and operations gap is solved by building a platform that can coordinate all of these moving pieces for many families in parallel, with AI handling the analysis and workflow management and PhD scientists handling the judgment calls. That is what Nome does.

The Three Real Pathways That Exist Today

If your child has a confirmed genetic diagnosis and you want to pursue a personalized therapy, there are three real pathways in 2026. Each has different eligibility criteria, different timelines, and different costs.

Most families will pursue more than one pathway. You can apply to n-Lorem while also building an academic collaboration while also engaging Nome to coordinate the broader program. These are not mutually exclusive.

What You Can Do Right Now If Your Child Has a Genetic Diagnosis

If the NYT piece made you want to move, here are the concrete steps to take.

Confirm a complete genetic diagnosis. Whole genome or whole exome sequencing with a confirmed pathogenic variant. A variant of uncertain significance is not enough to build a therapy on.

Start a patient cell line. Fibroblasts from a small skin biopsy, or iPSCs from blood. This is required for almost every personalized therapy pathway. Organizations like COMBINEDBrain run centralized biorepositories for 65+ rare disease groups.

Apply to nonprofit programs that fit your child. n-Lorem for ASO-addressable mutations in the liver, kidney, eye, or CNS. The review is free.

Submit your diagnosis to Nome for a free evaluation. Nome assesses which modalities apply to your child's specific mutation, estimates timeline and cost, and identifies the execution path across any tissue or modality. No charge. No commitment.

What Nome Does, In Plain Terms

About Nome

Nome Therapeutics is the Operating System for Personalized Therapeutics, turning every rare disease patient's genome into an actionable treatment plan and helping execute on it at the lowest cost and highest speed in the industry.

We exist because the NYT op-ed is right: the science works, and the gap is operational. Nome handles that gap. We use AI, paired with PhD scientists, to evaluate whether a personalized therapy is possible for your child, which modality fits (ASO, gene editing, gene therapy, drug repurposing), what the timeline and cost look like, and how to actually execute the program.

We work across modalities, coordinate with academic medical centers, CROs, and GMP manufacturers, and manage the regulatory pathway. We were founded by a rare disease patient who learned firsthand that the bottleneck is not the science. It is everything that has to happen around the science to deliver a treatment to one specific child.

If you read the NYT piece and want to find out what is possible for your family:

Submit your child's genetic diagnosis for a free evaluation at nome.bio

AI-generated, PhD-reviewed. No cost. No commitment.

REFERENCES

1. Ahrens-Nicklas R, Musunuru K, et al. "Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease." NEJM. May 2025. (Baby KJ, CPS1 deficiency, in vivo base editing)

2. Frangoul H, et al. RUBY Trial. NEJM. April 2026. (Reni-cel for sickle cell, 27/28 crisis-free)

3. FDA. "Framework for Plausible Mechanism in Individualized Therapies." February 23, 2026.

4. n-Lorem Foundation. "Celebrating Five Years." May 2025. (30+ patients treated, 160+ accepted, 25+ INDs filed)

5. Bauer DE, Orkin SH. "Genetic Medicine — Primed and Ready." NEJM Editorial. 2026.

6. STAT News. "Baby KJ researchers face FDA hurdle on scaling custom treatments." March 31, 2026.

7. Washington Post. "Scientists are inventing treatments for devastating diseases. There's just one problem." January 11, 2026.

This article is for informational purposes only and does not constitute medical advice.